Effect of Zinc supplementation in children and adolescents with Autoimmune thyroiditis, a type of thyroid disease
Not Applicable
Completed
- Conditions
- Health Condition 1: E063- Autoimmune thyroiditis
- Registration Number
- CTRI/2021/06/033920
- Lead Sponsor
- JIPMER Intramural Research Grant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Autoimmune Thyroiditis patients aged 3 â?? 18 years with Anti-TPO [Thyroid Peroxidase] (or) anti-Tg [Thyroglobulin] antibodies positivity with or without positive evidence in Ultrasonography
Exclusion Criteria
Patients who were treated with Zinc for other illnesses in the last 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link zinc supplementation to reduced thyroid auto-antibody levels in pediatric autoimmune thyroiditis?
How does zinc supplementation compare to levothyroxine in managing serum TPOAb and TgAb levels in CTRI/2021/06/033920 trial participants?
Which biomarkers (e.g., serum zinc, cytokine profiles) correlate with response to zinc in autoimmune thyroiditis (E063) pediatric patients?
What adverse events are associated with 12-week zinc supplementation in children with Hashimoto's thyroiditis or Graves' disease?
Are combination therapies involving zinc and selenium more effective than monotherapy for autoimmune thyroiditis in adolescents?